Weekly Roundup: Hot topics in the height of summer
NEZGLYAL® (leriglitazone) receives a positive CHMP opinion for the treatment of cerebral Adrenoleukodystrophy (cALD), a rare neurodegenerative disease
Minoryx Therapeutics and Neuraxpharm Group, announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended granting marketing authorisation approval under exceptional circumstances for NEZGLYAL® (leriglitazone) as a treatment for male cALD patients, aged 2-12 years with Gadolinium (Gd) negative brain lesions. European Commission approval is expected by the end of September 2026.
Xeltis raises an additional €20.5m of funding to advance aXess™ toward FDA approval and US commercial launch
Xeltis, a leading developer of transformative implants that enable the natural creation of living and long-lasting vessels, announced that it had raised an additional €20.5m of new funding from new and existing shareholders. Participating investors included the European Innovation Council, Invest-NL, VI Partners, EQT Life Sciences, DaVita and other current shareholders, alongside Horizon 3 Healthcare, a new investor who led the round.
Simris Group Appoints Biotechnology Expert Dr. Tiffany J. Vora as Strategic Advisor
Simris Group AB (SIMRIS B) announced the appointment of Dr. Tiffany J. Vora as a Strategic Advisor. Dr. Vora is a biotechnology scientist, entrepreneur, educator, and advisor with experience across molecular biology, genomics, biotechnology innovation, and drug discovery. Through her work with technology companies, startups, scientific organizations, and the broader innovation ecosystem, she has developed an extensive network across the U.S. biotechnology sector, particularly in Silicon Valley and the San Francisco Bay Area.
📢 Hot topic
Can you boil down what your company does into six words?
In this week’s Hot Topic, Stephen Adams outlines the importance of having a clear and concise company descriptor.
Watch the full video below and reach out to Optimum for help with your narrative development.
👥Industry events
Optimum’s 18th Annual Healthcare Investor Conference – London | 8th Oct 2026
Maximising Europe’s Potential – The theme of Optimum’s Annual Healthcare Investor Conference 2026.
The invitation only event takes place on Thursday 8th October and features leading speakers from the healthcare and investment communities. Register your interest in attending today: https://www.optimumcomms.com/irconference2026/
BIO-Europe 2026 – Cologne, Germany | 9–11th Nov 2026
Connecting with the global biotech community – Our CEO, Mary Clark, and Associate Director Zoe Bolt will be attending BIO-Europe 2026, one of the leading international partnering events for the life sciences industry.
The team look forward to meeting with companies, investors and potential partners to discuss collaboration opportunities. Get in touch to schedule a get-together.
Jefferies Global Healthcare Conference & Life Sciences Week – London | 15–20th Nov 2026
Plan ahead for Europe’s busiest week in healthcare 🌍
Join the mailing list to receive the official networking event guide, produced by Catalyst Advisors and Optimum Strategic Communications in partnership with Jefferies.
🧩 Sector moves
Keep up to date with the latest industry moves here.
That’s all folks! To stay in the know – subscribe to Optimum’s weekly wrap-up today!
